Kölner Konsensus Konferenz zur pulmonalen Hypertonie 2016
暂无分享,去创建一个
[1] S. Rosenkranz,et al. Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. , 2016, Journal of the American College of Cardiology.
[2] M. M. Hoeper,et al. Kommentar zu den 2015 ESC/ERS-Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie , 2016, Der Kardiologe.
[3] R. Wachter,et al. Left ventricular heart failure and pulmonary hypertension , 2015, European heart journal.
[4] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.
[5] D. Badesch,et al. [Definitions and diagnosis of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[6] W. Seeger,et al. Updated treatment algorithm of pulmonary arterial hypertension. , 2013, Journal of the American College of Cardiology.
[7] F. Martinez,et al. Pulmonary hypertension due to left heart diseases. , 2013, Journal of the American College of Cardiology.
[8] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[9] F. Martinez,et al. [Pulmonary hypertension in chronic lung diseases]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.